Oncology Pharma（ONPH）株式概要オンコロジー・ファーマ社は、がん治療薬の開発、製造、商業化を行う企業である。 詳細ONPH ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析最新の財務報告は1年以上前のものである US市場と比較して、過去 3 か月間の株価の変動が非常に大きい意味のある時価総額がありません ( $3M )すべてのリスクチェックを見るONPH Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.0810.0k% 割高 内在価値ディスカウントEst. Revenue$PastFuture-15k10k2016201920222025202620282031Revenue US$10.2kEarnings US$1.9kAdvancedSet Fair ValueView all narrativesOncology Pharma Inc. 競合他社Decoy TherapeuticsSymbol: NasdaqCM:DCOYMarket cap: US$2.8mBone BiologicsSymbol: NasdaqCM:BBLGMarket cap: US$2.3mProtoKinetixSymbol: OTCPK:PKTXMarket cap: US$2.2mOragenicsSymbol: NYSEAM:OGENMarket cap: US$2.5m価格と性能株価の高値、安値、推移の概要Oncology Pharma過去の株価現在の株価US$0.0852週高値US$0.3652週安値US$0.000001ベータ01ヶ月の変化0%3ヶ月変化1,900.00%1年変化79,900.00%3年間の変化-42.86%5年間の変化-99.65%IPOからの変化-99.90%最新ニュースお知らせ • Mar 12Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination TherapyOncology Pharma Inc. announced it is putting together a short list of contract research organizations (CROs) to assist in developing a research plan, along with indications for treatment in developing intellectual property towards commercialization. On February 26, 2021 the company announced that it had signed a worldwide license agreement with SYBLEU Inc. for a combination therapeutic platform for treating cancer. A spokesperson for the company stated it is anticipated there will be several indications this therapeutic will be used for in treating various cancers. It will be the role of the selected CRO to carry out research on behalf of the company. The selected CRO will provide a plan based on its assessment of the intellectual property of Oncology Pharma and assist the company in targeting the first indication for use.お知らせ • Mar 06Oncology Pharma Inc. Moves to Fund Lead Drug Formulation & IND-Enabling StudiesOncology Pharma Inc. announced the initiation of formal drug development and preclinical planning for its lead drug product, based upon proprietary nanoemulsion technology licensed from NanoSmart Pharmaceuticals. Oncology Pharma will be providing the initial funds to develop and evaluate a dactinomycin nanoemulsion drug product. A version of this product originally received FDA Orphan Drug Designation in 2015. Oncology Pharma has secured access to a broad range of proprietary intellectual property with the potential to make novel drug products to treat cancer that are both safer and more effective than the original drug(s) currently in the market. Oncology Pharma has initiated discussions with NanoSmart on near-term goals including analytical method validation and drug product characterization. Once complete, formal preclinical safety and veterinary clinical studies will be pursued. Veterinary drug development will serve a current and growing need for better treatment options. Data from this project may also be applied towards future regulatory approval to initial human clinical studies for the same drug formulation.お知らせ • Feb 27Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory AgentOncology Pharma Inc. announced that it has executed a world-wide Licensing Agreement with Sybleu Inc. for its Cancer therapy by intratumoral injection of a chemotherapeutic agent in combination with a bioactive immunostimulatory agent. The chemotherapeutic agent of claim is AQ4 & AQ4N. The bioactive agent is derived from the group of TNF-alpha, GM-CSF, IL-4, IL-2, IL-12, IL-23, DNA, RNA, Nucleic Acids and CD-40 Ligand. The concept of this invention is the simultaneous intratumoral injection of a chemotherapeutic agents in combination with immunomodulatory agents in sustained release formulations. The chemotherapeutic agent is for the purpose of directly killing the tumor cells for the release of antigens while the immunomodulatory protein or factor is to stimulate the antigenic response of the host to the antigens.Oncology Pharma is excited about expanding its portfolio in oncology and therapeutics. The company sees a synergy within the portfolio and is continuously building within its expertise while utilizing its Board and Scientific Advisory Board to seek out opportunities to enhance its position within the field of oncology.お知らせ • Feb 23Oncology Pharma Extends Licensing Agreement with Nanosmart Pharmaceuticals, Inc. for Veterinary OncologyOncology Pharma, Inc. announce that it has extended a world-wide Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for use in the growing Veterinary Oncology market. Nanosmart possesses proprietary technology and intellectual property rights for the development of liposomal and/or emulsion-based drug formulations that incorporate anti-nuclear antibodies (ANA). ANA may be utilized as a targeting agent in pharmaceutical compounds to deliver active pharmaceutical ingredients to tumor sites, potentially resulting in safer and more effective cancer therapies. ANA-conjugated formulations like those licensed from NanoSmart present an opportunity to deliver better healthcare options for a growing and receptive market.お知らせ • Feb 18Oncology Pharma Inc. Announces Henry Smith as New Chairman to Its Scientific Advisory BoardOncology Pharma Inc. announced that Dr. Henry Smith has accepted the role of Chairman of the Scientific Advisory Board. Dr. Henry Smith has over 50 years’ experience in Healthcare. Dr. Smith has worked to develop novel technologies to serve the healthcare industry, including one of the first CEA tests for detecting cancer. In 1966, Dr. Smith published the first report that normal lymphocytes had an innate immunity to destroy cancer cells. He is the co-founder of several biotech companies, and has maintained a keen interest in developing a variety of immunological methods to diagnose and treat cancer throughout his career. Dr. Smith has a Ph.D in Medical Immunology from the University of Leeds, England.お知らせ • Feb 10Oncology Pharma Renews Licensing Agreement with Ribera Solutions LLC for Its Connect2med Clinical Trials PlatformOncology Pharma Inc. announced that it has renewed its world-wide Licensing Agreement with Ribera Solutions (under its tradename “Connect2Med”) with exclusivity for oncology, including drug development, clinical trials, personalized oncology and therapeutics. Connect2Med provides a motivating trial experience through increased engagement and easy to use communication tools. They have access to a dedicated trial specific portal (patient facing app), where they can perform functions like eDiary, ePRO, telehealth visits. The platform is FHIR compatible and easily integrates with EHR, CTMS, CRM from major vendors in the industry. Patients’ workflow can be automated through a set of digital workflows, with automated interventions and escalation when needed. Sites and CROs can post upcoming trials in a public space for all to see, boosting public awareness through social sharing. Site owners and Sponsors have access to impactful data, metrics and reports that allow them to make strategic decisions to improve retention, growth, performance, satisfaction and ROI.最新情報をもっと見るRecent updatesお知らせ • Mar 12Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination TherapyOncology Pharma Inc. announced it is putting together a short list of contract research organizations (CROs) to assist in developing a research plan, along with indications for treatment in developing intellectual property towards commercialization. On February 26, 2021 the company announced that it had signed a worldwide license agreement with SYBLEU Inc. for a combination therapeutic platform for treating cancer. A spokesperson for the company stated it is anticipated there will be several indications this therapeutic will be used for in treating various cancers. It will be the role of the selected CRO to carry out research on behalf of the company. The selected CRO will provide a plan based on its assessment of the intellectual property of Oncology Pharma and assist the company in targeting the first indication for use.お知らせ • Mar 06Oncology Pharma Inc. Moves to Fund Lead Drug Formulation & IND-Enabling StudiesOncology Pharma Inc. announced the initiation of formal drug development and preclinical planning for its lead drug product, based upon proprietary nanoemulsion technology licensed from NanoSmart Pharmaceuticals. Oncology Pharma will be providing the initial funds to develop and evaluate a dactinomycin nanoemulsion drug product. A version of this product originally received FDA Orphan Drug Designation in 2015. Oncology Pharma has secured access to a broad range of proprietary intellectual property with the potential to make novel drug products to treat cancer that are both safer and more effective than the original drug(s) currently in the market. Oncology Pharma has initiated discussions with NanoSmart on near-term goals including analytical method validation and drug product characterization. Once complete, formal preclinical safety and veterinary clinical studies will be pursued. Veterinary drug development will serve a current and growing need for better treatment options. Data from this project may also be applied towards future regulatory approval to initial human clinical studies for the same drug formulation.お知らせ • Feb 27Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory AgentOncology Pharma Inc. announced that it has executed a world-wide Licensing Agreement with Sybleu Inc. for its Cancer therapy by intratumoral injection of a chemotherapeutic agent in combination with a bioactive immunostimulatory agent. The chemotherapeutic agent of claim is AQ4 & AQ4N. The bioactive agent is derived from the group of TNF-alpha, GM-CSF, IL-4, IL-2, IL-12, IL-23, DNA, RNA, Nucleic Acids and CD-40 Ligand. The concept of this invention is the simultaneous intratumoral injection of a chemotherapeutic agents in combination with immunomodulatory agents in sustained release formulations. The chemotherapeutic agent is for the purpose of directly killing the tumor cells for the release of antigens while the immunomodulatory protein or factor is to stimulate the antigenic response of the host to the antigens.Oncology Pharma is excited about expanding its portfolio in oncology and therapeutics. The company sees a synergy within the portfolio and is continuously building within its expertise while utilizing its Board and Scientific Advisory Board to seek out opportunities to enhance its position within the field of oncology.お知らせ • Feb 23Oncology Pharma Extends Licensing Agreement with Nanosmart Pharmaceuticals, Inc. for Veterinary OncologyOncology Pharma, Inc. announce that it has extended a world-wide Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for use in the growing Veterinary Oncology market. Nanosmart possesses proprietary technology and intellectual property rights for the development of liposomal and/or emulsion-based drug formulations that incorporate anti-nuclear antibodies (ANA). ANA may be utilized as a targeting agent in pharmaceutical compounds to deliver active pharmaceutical ingredients to tumor sites, potentially resulting in safer and more effective cancer therapies. ANA-conjugated formulations like those licensed from NanoSmart present an opportunity to deliver better healthcare options for a growing and receptive market.お知らせ • Feb 18Oncology Pharma Inc. Announces Henry Smith as New Chairman to Its Scientific Advisory BoardOncology Pharma Inc. announced that Dr. Henry Smith has accepted the role of Chairman of the Scientific Advisory Board. Dr. Henry Smith has over 50 years’ experience in Healthcare. Dr. Smith has worked to develop novel technologies to serve the healthcare industry, including one of the first CEA tests for detecting cancer. In 1966, Dr. Smith published the first report that normal lymphocytes had an innate immunity to destroy cancer cells. He is the co-founder of several biotech companies, and has maintained a keen interest in developing a variety of immunological methods to diagnose and treat cancer throughout his career. Dr. Smith has a Ph.D in Medical Immunology from the University of Leeds, England.お知らせ • Feb 10Oncology Pharma Renews Licensing Agreement with Ribera Solutions LLC for Its Connect2med Clinical Trials PlatformOncology Pharma Inc. announced that it has renewed its world-wide Licensing Agreement with Ribera Solutions (under its tradename “Connect2Med”) with exclusivity for oncology, including drug development, clinical trials, personalized oncology and therapeutics. Connect2Med provides a motivating trial experience through increased engagement and easy to use communication tools. They have access to a dedicated trial specific portal (patient facing app), where they can perform functions like eDiary, ePRO, telehealth visits. The platform is FHIR compatible and easily integrates with EHR, CTMS, CRM from major vendors in the industry. Patients’ workflow can be automated through a set of digital workflows, with automated interventions and escalation when needed. Sites and CROs can post upcoming trials in a public space for all to see, boosting public awareness through social sharing. Site owners and Sponsors have access to impactful data, metrics and reports that allow them to make strategic decisions to improve retention, growth, performance, satisfaction and ROI.お知らせ • Jan 29Oncology Pharma Announces the Appointment of James Smith as New Chief Financial OfficerOncology Pharma Inc. that it has retained the services of Mr. James Smith, CPA as its new Chief Financial Officer. Mr. James Smith, CPA is a seasoned executive officer with experience encompassing multiple public and private companies across a variety of industries. His prior experience includes CEO and/or CFO in two fully reporting SEC registrants as well as numerous OTC Pink Sheet companies in either the CFO, outside accountant or CEO capacities. In addition, during his employment with two national accounting firms and in his own CPA firm practice, Mr. Smith has worked with multiple Family Offices and investors in assisting them with their operations, capital placement, organizational strategy and structure, with an emphasis on tax and estate planning. Oncology Pharma is pleased to welcome Mr. Smith aboard as the Company is working towards expanding its portfolio and financing.株主還元ONPHUS BiotechsUS 市場7D33.1%-4.9%-1.0%1Y79,900.0%28.1%23.3%株主還元を見る業界別リターン: ONPH過去 1 年間で28.1 % の収益を上げたUS Biotechs業界を上回りました。リターン対市場: ONPH過去 1 年間で23.3 % の収益を上げたUS市場を上回りました。価格変動Is ONPH's price volatile compared to industry and market?ONPH volatilityONPH Average Weekly Movement89.6%Biotechs Industry Average Movement10.9%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.2%安定した株価: ONPHの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: ONPHの 週次ボラティリティ は過去 1 年間で3811%から90%に減少しましたが、依然としてUS株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1993n/aGeorge Malesekwww.oncology-pharma.comオンコロジー・ファーマ社は、がん治療薬の開発、製造、商業化を行う企業である。同社は、COVID-19ウイルスの治療機会を探索するため、Kalos Therapeutics Inc.と提携およびライセンス契約を結んでいる。同社は以前はSourcingLink.net Inc.として知られていたが、2019年6月に社名をOncology Pharma Inc.に変更した。オンコロジー・ファーマ・インクは1993年に法人化され、カリフォルニア州サンフランシスコを拠点としている。もっと見るOncology Pharma Inc. 基礎のまとめOncology Pharma の収益と売上を時価総額と比較するとどうか。ONPH 基礎統計学時価総額US$3.48m収益（TTM）-US$15.27k売上高(TTM)US$10.21k0.0xP/Sレシオ0.0xPER（株価収益率ONPH は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計ONPH 損益計算書（TTM）収益US$10.21k売上原価US$0売上総利益US$10.21kその他の費用US$25.48k収益-US$15.27k直近の収益報告Mar 31, 2013次回決算日該当なし一株当たり利益（EPS）0グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0.0%ONPH の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 03:41終値2026/05/20 00:00収益2013/03/31年間収益2013/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Oncology Pharma Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 12Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination TherapyOncology Pharma Inc. announced it is putting together a short list of contract research organizations (CROs) to assist in developing a research plan, along with indications for treatment in developing intellectual property towards commercialization. On February 26, 2021 the company announced that it had signed a worldwide license agreement with SYBLEU Inc. for a combination therapeutic platform for treating cancer. A spokesperson for the company stated it is anticipated there will be several indications this therapeutic will be used for in treating various cancers. It will be the role of the selected CRO to carry out research on behalf of the company. The selected CRO will provide a plan based on its assessment of the intellectual property of Oncology Pharma and assist the company in targeting the first indication for use.
お知らせ • Mar 06Oncology Pharma Inc. Moves to Fund Lead Drug Formulation & IND-Enabling StudiesOncology Pharma Inc. announced the initiation of formal drug development and preclinical planning for its lead drug product, based upon proprietary nanoemulsion technology licensed from NanoSmart Pharmaceuticals. Oncology Pharma will be providing the initial funds to develop and evaluate a dactinomycin nanoemulsion drug product. A version of this product originally received FDA Orphan Drug Designation in 2015. Oncology Pharma has secured access to a broad range of proprietary intellectual property with the potential to make novel drug products to treat cancer that are both safer and more effective than the original drug(s) currently in the market. Oncology Pharma has initiated discussions with NanoSmart on near-term goals including analytical method validation and drug product characterization. Once complete, formal preclinical safety and veterinary clinical studies will be pursued. Veterinary drug development will serve a current and growing need for better treatment options. Data from this project may also be applied towards future regulatory approval to initial human clinical studies for the same drug formulation.
お知らせ • Feb 27Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory AgentOncology Pharma Inc. announced that it has executed a world-wide Licensing Agreement with Sybleu Inc. for its Cancer therapy by intratumoral injection of a chemotherapeutic agent in combination with a bioactive immunostimulatory agent. The chemotherapeutic agent of claim is AQ4 & AQ4N. The bioactive agent is derived from the group of TNF-alpha, GM-CSF, IL-4, IL-2, IL-12, IL-23, DNA, RNA, Nucleic Acids and CD-40 Ligand. The concept of this invention is the simultaneous intratumoral injection of a chemotherapeutic agents in combination with immunomodulatory agents in sustained release formulations. The chemotherapeutic agent is for the purpose of directly killing the tumor cells for the release of antigens while the immunomodulatory protein or factor is to stimulate the antigenic response of the host to the antigens.Oncology Pharma is excited about expanding its portfolio in oncology and therapeutics. The company sees a synergy within the portfolio and is continuously building within its expertise while utilizing its Board and Scientific Advisory Board to seek out opportunities to enhance its position within the field of oncology.
お知らせ • Feb 23Oncology Pharma Extends Licensing Agreement with Nanosmart Pharmaceuticals, Inc. for Veterinary OncologyOncology Pharma, Inc. announce that it has extended a world-wide Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for use in the growing Veterinary Oncology market. Nanosmart possesses proprietary technology and intellectual property rights for the development of liposomal and/or emulsion-based drug formulations that incorporate anti-nuclear antibodies (ANA). ANA may be utilized as a targeting agent in pharmaceutical compounds to deliver active pharmaceutical ingredients to tumor sites, potentially resulting in safer and more effective cancer therapies. ANA-conjugated formulations like those licensed from NanoSmart present an opportunity to deliver better healthcare options for a growing and receptive market.
お知らせ • Feb 18Oncology Pharma Inc. Announces Henry Smith as New Chairman to Its Scientific Advisory BoardOncology Pharma Inc. announced that Dr. Henry Smith has accepted the role of Chairman of the Scientific Advisory Board. Dr. Henry Smith has over 50 years’ experience in Healthcare. Dr. Smith has worked to develop novel technologies to serve the healthcare industry, including one of the first CEA tests for detecting cancer. In 1966, Dr. Smith published the first report that normal lymphocytes had an innate immunity to destroy cancer cells. He is the co-founder of several biotech companies, and has maintained a keen interest in developing a variety of immunological methods to diagnose and treat cancer throughout his career. Dr. Smith has a Ph.D in Medical Immunology from the University of Leeds, England.
お知らせ • Feb 10Oncology Pharma Renews Licensing Agreement with Ribera Solutions LLC for Its Connect2med Clinical Trials PlatformOncology Pharma Inc. announced that it has renewed its world-wide Licensing Agreement with Ribera Solutions (under its tradename “Connect2Med”) with exclusivity for oncology, including drug development, clinical trials, personalized oncology and therapeutics. Connect2Med provides a motivating trial experience through increased engagement and easy to use communication tools. They have access to a dedicated trial specific portal (patient facing app), where they can perform functions like eDiary, ePRO, telehealth visits. The platform is FHIR compatible and easily integrates with EHR, CTMS, CRM from major vendors in the industry. Patients’ workflow can be automated through a set of digital workflows, with automated interventions and escalation when needed. Sites and CROs can post upcoming trials in a public space for all to see, boosting public awareness through social sharing. Site owners and Sponsors have access to impactful data, metrics and reports that allow them to make strategic decisions to improve retention, growth, performance, satisfaction and ROI.
お知らせ • Mar 12Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination TherapyOncology Pharma Inc. announced it is putting together a short list of contract research organizations (CROs) to assist in developing a research plan, along with indications for treatment in developing intellectual property towards commercialization. On February 26, 2021 the company announced that it had signed a worldwide license agreement with SYBLEU Inc. for a combination therapeutic platform for treating cancer. A spokesperson for the company stated it is anticipated there will be several indications this therapeutic will be used for in treating various cancers. It will be the role of the selected CRO to carry out research on behalf of the company. The selected CRO will provide a plan based on its assessment of the intellectual property of Oncology Pharma and assist the company in targeting the first indication for use.
お知らせ • Mar 06Oncology Pharma Inc. Moves to Fund Lead Drug Formulation & IND-Enabling StudiesOncology Pharma Inc. announced the initiation of formal drug development and preclinical planning for its lead drug product, based upon proprietary nanoemulsion technology licensed from NanoSmart Pharmaceuticals. Oncology Pharma will be providing the initial funds to develop and evaluate a dactinomycin nanoemulsion drug product. A version of this product originally received FDA Orphan Drug Designation in 2015. Oncology Pharma has secured access to a broad range of proprietary intellectual property with the potential to make novel drug products to treat cancer that are both safer and more effective than the original drug(s) currently in the market. Oncology Pharma has initiated discussions with NanoSmart on near-term goals including analytical method validation and drug product characterization. Once complete, formal preclinical safety and veterinary clinical studies will be pursued. Veterinary drug development will serve a current and growing need for better treatment options. Data from this project may also be applied towards future regulatory approval to initial human clinical studies for the same drug formulation.
お知らせ • Feb 27Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory AgentOncology Pharma Inc. announced that it has executed a world-wide Licensing Agreement with Sybleu Inc. for its Cancer therapy by intratumoral injection of a chemotherapeutic agent in combination with a bioactive immunostimulatory agent. The chemotherapeutic agent of claim is AQ4 & AQ4N. The bioactive agent is derived from the group of TNF-alpha, GM-CSF, IL-4, IL-2, IL-12, IL-23, DNA, RNA, Nucleic Acids and CD-40 Ligand. The concept of this invention is the simultaneous intratumoral injection of a chemotherapeutic agents in combination with immunomodulatory agents in sustained release formulations. The chemotherapeutic agent is for the purpose of directly killing the tumor cells for the release of antigens while the immunomodulatory protein or factor is to stimulate the antigenic response of the host to the antigens.Oncology Pharma is excited about expanding its portfolio in oncology and therapeutics. The company sees a synergy within the portfolio and is continuously building within its expertise while utilizing its Board and Scientific Advisory Board to seek out opportunities to enhance its position within the field of oncology.
お知らせ • Feb 23Oncology Pharma Extends Licensing Agreement with Nanosmart Pharmaceuticals, Inc. for Veterinary OncologyOncology Pharma, Inc. announce that it has extended a world-wide Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for use in the growing Veterinary Oncology market. Nanosmart possesses proprietary technology and intellectual property rights for the development of liposomal and/or emulsion-based drug formulations that incorporate anti-nuclear antibodies (ANA). ANA may be utilized as a targeting agent in pharmaceutical compounds to deliver active pharmaceutical ingredients to tumor sites, potentially resulting in safer and more effective cancer therapies. ANA-conjugated formulations like those licensed from NanoSmart present an opportunity to deliver better healthcare options for a growing and receptive market.
お知らせ • Feb 18Oncology Pharma Inc. Announces Henry Smith as New Chairman to Its Scientific Advisory BoardOncology Pharma Inc. announced that Dr. Henry Smith has accepted the role of Chairman of the Scientific Advisory Board. Dr. Henry Smith has over 50 years’ experience in Healthcare. Dr. Smith has worked to develop novel technologies to serve the healthcare industry, including one of the first CEA tests for detecting cancer. In 1966, Dr. Smith published the first report that normal lymphocytes had an innate immunity to destroy cancer cells. He is the co-founder of several biotech companies, and has maintained a keen interest in developing a variety of immunological methods to diagnose and treat cancer throughout his career. Dr. Smith has a Ph.D in Medical Immunology from the University of Leeds, England.
お知らせ • Feb 10Oncology Pharma Renews Licensing Agreement with Ribera Solutions LLC for Its Connect2med Clinical Trials PlatformOncology Pharma Inc. announced that it has renewed its world-wide Licensing Agreement with Ribera Solutions (under its tradename “Connect2Med”) with exclusivity for oncology, including drug development, clinical trials, personalized oncology and therapeutics. Connect2Med provides a motivating trial experience through increased engagement and easy to use communication tools. They have access to a dedicated trial specific portal (patient facing app), where they can perform functions like eDiary, ePRO, telehealth visits. The platform is FHIR compatible and easily integrates with EHR, CTMS, CRM from major vendors in the industry. Patients’ workflow can be automated through a set of digital workflows, with automated interventions and escalation when needed. Sites and CROs can post upcoming trials in a public space for all to see, boosting public awareness through social sharing. Site owners and Sponsors have access to impactful data, metrics and reports that allow them to make strategic decisions to improve retention, growth, performance, satisfaction and ROI.
お知らせ • Jan 29Oncology Pharma Announces the Appointment of James Smith as New Chief Financial OfficerOncology Pharma Inc. that it has retained the services of Mr. James Smith, CPA as its new Chief Financial Officer. Mr. James Smith, CPA is a seasoned executive officer with experience encompassing multiple public and private companies across a variety of industries. His prior experience includes CEO and/or CFO in two fully reporting SEC registrants as well as numerous OTC Pink Sheet companies in either the CFO, outside accountant or CEO capacities. In addition, during his employment with two national accounting firms and in his own CPA firm practice, Mr. Smith has worked with multiple Family Offices and investors in assisting them with their operations, capital placement, organizational strategy and structure, with an emphasis on tax and estate planning. Oncology Pharma is pleased to welcome Mr. Smith aboard as the Company is working towards expanding its portfolio and financing.
